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Administration of the halogenated nucleoside, 5-bromodeoxyuridine 
(BUDR) to mammalian systems is followed by its incorporation into DNA 
resulting in an increased susceptibility of mammalian cells to the lethal effects 
of x-irradiation [l-4] . Because tumor cells generally have higher turnover 
and therefore a higher DNA synthesis rate than the surrounding normal tissues, 
this radiosensitization effect of BUDR makes it a useful agent in the treatment 
of neoplastic disorders. 
Several clinical trials have been conducted to evaluate the efficacy of BUDR 
[5--81. The initial human study utilized *2Br-radiolabeled BUDR and 
demonstrated the drug’s rapid plasma clearance. Subsequent trials [6, 71 using 
continuous intracarotid arterial infusions of BUDR in the treatment of gliomas 
did not include drug level data. In a recent study [8] BUDR was administered 
by intravenous infusion for 12 h per day for fourteen days. Plasma BUDR 
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levels were determined 
(HPLC) method which 
following each injection. 
This paper describes a 
using a high-performance liquid chromatographic 
necessitated washing the column with methanol 
rapid, accurate and sensitive HPLC procedure for the 
simultaneous measurement of BUDRand bromouracil (BU) in plasma and urine 
samples. 
MATERIALS AND METHODS 
Reagents 
Ethyl acetate and methanol were purchased from Burdick & Jackson Labs. 
(Muskegon, MI, U.S.A.), monobasic ammonium phosphate from J.T. Baker 
(Phillipsburg, NJ, U.S.A.), potassium hydroxide and ammonium sulfate from 
Mallinckrodt (St. Louis, MO, U.S.A.), BUDR, bromouracil and iodouracil 
from Sigma (St. Louis, MO, U.S.A.). 
Stock solutions 
Bromodeoxyuridine solution (0.5 mg/ml in methanol), bromouracil solution 
(0.5 mg/ml in methanol) and iodouracil (IU) solution (1.0 mg/ml in methanol) 
were prepared and stored at -20°C. Saturated ammonium sulfate solution and 
‘0.5 M potassium hydroxide solution were prepared and stored at room 
temperature. 
Standards 
BUDR and BU stock solutions were mixed 1:l and diluted with water to 
yield the first BUDR+BU standard solution (standard I = 100 pg/ml of each). 
Standard I was further diluted to 10 pg/ml of each to give the second standard 
solution (standard II). Iodouracil stock solution was diluted with water to yield 
the internal standard solution containing 10 pg/ml IU. 
Quality control samples at three concentrations (200, 800 and 1600 ng/ml 
each of BUDR and BU) were prepared by spiking blank plasma with the 
appropriate volumes of the BUDR+BU standards. After mixing, l.O-ml 
aliquots were transferred to glass tubes, tightly capped, and stored frozen at 
-30°C. Two quality control samples of each concentration were included with 
every group of experimental samples to be analyzed. 
Chroma tographic conditions 
The HPLC unit included a Waters Assoc. Model 6000A pump, a Waters 
Assoc. Model 440 UV/VIS absorbance detector with a 280~nm filter, a Waters 
Assoc. Model ‘710B WISP autosampler and a Hewlett-Packard Model 3390A 
integrator. The column used was a DuPont Zorbax Cs reversed-phase column 
(25 cm X 4.6 mm I.D., spherical, 6 E.trn particle size). The mobile phase was a 
0.05 M ammonium phosphate buffer (pH = 7.3)-methanol mixture with a 
final methanol concentration of 12%. The flow-rate was set at 1.0 ml/mm 
Under these conditions the retention times of BU, IU and BUDR were 5.1, 
7.0 and 8.0 min, respectively. Fig. 1 depicts the chemical structures of BU, 









Fig. 1. Chemical structures of (a) 5-bromodeoxyuridine (BUDR), (b) 5-bromouracil (BU) 
and (c) B-iodouracil (IU), the internal standard. 
Sample preparation 
To glass tubes (15 ml capacity) were added 1.0 ml plasma, 100 ~1 internal 
standard solution (1000 ng IU), 2.0 ml saturated ammonium sulfate solution, 
100 ~1 ammonium phosphate buffer, pH 6.7, and 8.0 ml ethyl acetate. The 
tubes were tightly capped and shaken for 15 min at room temperature. In 
unknown plasma samples where drug concentrations were expected to exceed 
2000 ng/ml, a smaller volume was utilized with the difference to 1.0 ml made 
up with an appropriate volume of blank plasma. After centrifugation (room 
temperature) for 10 min at 1200 g, the ethyl acetate phase was transferred to 
clean conical-bottomed glass tubes and concentrated to approximately 1.0 ml 
by evaporation in a waterbath under a stream of air. To each sample were 
added 400 ~1 of 0.5 M potassium hydroxide and the drugs and internal 
standard back-extracted by shaking for 15 min at room temperature. After 
centrifugation (room temperature) at 1000 g for 10 min, the ethyl acetate 
phase was removed by aspiration. A 3.0-30.0 ~1 aliquot of the alkaline 
aqueous phase was injected for HPLC analysis. The analysis of urine samples 
was conducted in an identical fashion. 
Standard calibration curve 
Blank plasma samples were spiked in duplicate with the appropriate volumes 
of BUDR+BU standard solutions I or II to concentrations ranging from 
0 to 2000 ng/ml and subjected to the sample preparation procedure described 
above. Calibration curves were run with each set of experimental samples. 
Calculations 
Calibration curves were constructed by plotting the ratio of the peak height 
of each drug to that of the internal standard as a function of the plasma drug 
concentration. The best-fit straight line was determined using the method of 
least squares. The BU and BUDR concentrations of unknown samples were 
calculated from the least-squares regression line of the calibration curve. 
RESULTS AND DISCUSSION 
Under the described conditions, the retention times of BU, internal standard 
a) 
b) 
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Fig. 2. ‘I’ypical chromatograms of (a) control plasma, (b) a quality control sample containing 
800 ng/ml BU and 800 ng/ml BUDR in plasma and (c) a plasma sample obtained from a dog 
15 min post-administration of 4.0 mg/kg BUDR as an intravenous bolus injection. Internal 
standard (IU) was added to each sample. 
and BUDR were 5.1, 7.0 and 8.0 min, respectively. Fig. 2 illustrates typical 
chromatograms for control plasma, a quality control plasma sample containing 
800 ng/ml BU and 800 ng/ml BUDR, and a plasma sample obtained from a dog 
15 min post-administration of 4.0 mg/kg BUDR as an intravenous bolus injec- 
tion. The plasma samples elicit no interfering peaks. The total analysis time 
required for each run was 15 min. The validity of the assay procedure was 
established through a careful study of the linearity of response, reproducibility, 
accuracy and precision. 
The peak height ratio was directly proportional to the BU and BUDR 
concentrations over a range of 60-2000 ng/ml and 100-2000 ng/ml, respec- 
tively. The best-fit lines were obtained using linear regression analyses. The 
results of the regression analyses for BU and BUDR were: y = 0.00184~ + 
0.0171 (r = 0.9980) and y = 0.00105~ + 0.094 (r = 0.9940), respectively. 
The accuracy and precision of the method were assessed by seeding plasma 
at BU and BUDR concentrations of 200, 800 and 1600 ng/ml of each. 
Triplicate quality control samples at each concentration were assayed on each 
of three consecutive days. Table I gives the results of this experiment. The 
precision of the assay was found to have coefficients of variation (C.V., %) 
ranging from 6.2% to 10.6% and 5.8% to 10.3% for BU and BUDR, respec- 
tively. The concentration means for the seeded control samples were found to 
be with -2.2% to +0.4% and -12.2% to -4.8% of the theoretical values for 
BU and BUDR, respectively. 
Application of the method developed was demonstrated by measuring 
the plasma BU and BUDR levels in a dog following the intravenous bolus 
administration of a 4.0 mg/kg BUDR dose. Peripheral venous blood samples 
were withdrawn at regular intervals and the plasma obtained was used for drug 
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TABLE I 
BROMOURACIL AND BROMODEOXYURIDINE CONCENTRATIONS IN SEEDED 
CONTROL SAMPLES ASSAYED OVER A THREE-DAY PERIOD 
Day Concentration (ng/ml) 
Bromouracil Bromodeoxyuridine 
1 213.2 809.8 1511.1 191.6 770.3 1455.3 
197.5 784.7 1517.6 163.1 737.6 1499.7 
204.4 739.6 1406.3 162.1 692.5 1382.8 
2 216.2 802.2 1628.8 190.9 702.6 1453.1 
221.3 860.6 1721.5 190.9 929.8 1604.5 
221.3 806.2 1705.4 185.0 699.2 1656.0 
. 
3 173.2 820.7 1576.0 163.8 831.4 1618.2 
199.2 718.8 1571.0 183.6 737.8 1510.2 
160.8 699.4 1576.0 149.6 716.1 1534.5 
Mean 200.8 782.4 1579.3 175.6 757.5 1523.8 
:? 
(96) 
21.3 10 6 52.5 6 7 98.1 6 2 15.9 9 1 77.8 10 3 89.0 
5.8 
Percent from 
theoretical +0.4 -2.2 -1.3 -12.2 -5.3 -4.8 
TIME bin) 
Fig. 3. The plasma BUDR and BU concentration-time profiles in a dog following the intra- 
venous bolus administration of 4.0 mg/kg BUDR. (e) BUDR; (0) BU. 
and metabolite analysis. Fig. 3 illustrates the plasma BUDR and BU concen- 
trations versus time plots from this experiment. The BUDR data are well 
described by the function: 
CBUDR = 1539e -‘Jo’ + 28728e-0*54*’ 
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The distribution half-life (t~,+~) of BUDR was 1.28 min and the elimination 
half-life (+) was 4.23 min. The BU data are also well described by a biex- 
ponential function: 
CBu = 3472e-o*560f + 1336e_0*‘05t 
Here, the tso, of BU was 1.24 min and the tsB was 6.6 min. 
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